Overview |
bsm-70248M |
Rhodopsin Antibody |
WB, IHC |
Specific for endogenous levels of the ~39 kDa rhodopsin protein. |
Amphibians, Most Mammals |
Specifications |
Unconjugated |
Mouse |
Purified native bovine rhodopsin. |
Monoclonal |
1D4 |
IgG1 |
Lot Dependent |
Purified by Protein G. |
10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
Target |
509933 |
P02699 |
CSNBAD1 antibody, MGC138309 antibody, MGC138311 antibody, OPN 2 antibody, OPN2 antibody, opsd antibody, OPSD_HUMAN antibody, opsin 2 antibody, Opsin 2 rod pigment antibody, Opsin-2 antibody, Opsin2 antibody, Retinitis Pigmentosa 4 antibody, Retinitis pigmentosa 4 autosomal dominant antibody, RHO antibody, Rhodopsin antibody, RP 4 antibody, RP4 antibody |
Rhodopsin is a photoreceptor protein found in retinal rods. It is a complex formed by the binding of retinaldehyde, the oxidized form of retinol, to the protein opsin and undergoes a series of complex reactions in response to visible light resulting in the transmission of nerve impulses to the brain. Mutation of the rhodopsin gene is a major contributor to various retinopathies such as retinitis pigmentosa. The disease-causing protein generally aggregates with ubiquitin in inclusion bodies, disrupts the intermediate filament network and impairs the ability of the cell to degrade non-functioning proteins which leads to photoreceptor apoptosis (Berson et al., 1991). Other mutations on rhodopsin lead to X-linked congenital stationary night blindness, mainly due to constitutive activation, when the mutations occur around the chromophore binding pocket of rhodopsin (Dryja et al.,1993). Several other pathological states relating to rhodopsin have been discovered including poor post-Golgi trafficking, dysregulative activation, rod outer segment instability and arrestin binding. |
Application Dilution |
WB |
1:300-5000 |
IHC |
|